LENZ Therapeutics, Inc. (LENZ) shareholders
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (13.60%), Peter Kolchinsky (13.60%) and 1 more | 4,265,106 | 13.60% | 13D (active) amendment | Nov 5, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (15.10%), Rajeev Shah (15.10%) and 1 more | 4,260,606 | 15.10% | 13D (active) amendment | May 7, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (11.80%) | 3,702,718 | 11.80% | 13G (passive) amendment | Dec 31, 2025 |
| Alpha Wave Ventures GP, Ltd | 3,612,211 | – | 13G (passive) | Mar 21, 2024 |
| Matthew Porteus | 3,548,529 | 6.10% | 13G (passive) amendment | Dec 31, 2023 |
| Tang Capital Partners, LP Joint filing with Tang Capital Management, LLC (5.40%), Kevin Tang (5.40%) | 3,117,843 | 5.40% | 13G (passive) | Jan 24, 2024 |
| BML Investment Partners, L.P. | 2,110,727 | 6.70% | 13G (passive) | Nov 2, 2026 |
| BlackRock, Inc. | 1,804,099 | 5.80% | 13G (passive) | Mar 31, 2026 |
| BlackRock Portfolio Management LLC | 1,645,489 | 5.20% | 13G (passive) | Sep 30, 2026 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.10%), Millennium Group Management LLC (5.10%) | 1,603,512 | 5.10% | 13G (passive) | Jun 23, 2026 |
| Squarepoint Ops LLC Joint filing with Squarepoint Capital LLP (5.10%), Squarepoint Operations Private Limited (5.10%) and 2 more | 1,593,246 | 5.10% | 13G (passive) | Apr 1, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LENZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 4,178,823 | 13.30% | $23.74M | – | 0.21% |
| Alpha Wave Global, LP | 3,612,211 | 11.50% | $20.52M | – | 0.33% |
| FMR LLC | 3,558,905 | 11.33% | $20.21M | −38,879 | 0.00% |
| Versant Venture Management, LLC | 2,656,888 | 8.46% | $15.09M | – | 9.28% |
| BlackRock, Inc. | 2,292,121 | 7.30% | $13.02M | +315,298 | 0.00% |
| Squarepoint Ops LLC | 1,747,096 | 5.56% | $9.92M | +240,597 | 0.01% |
| abrdn plc | 1,547,883 | 4.93% | $8.79M | +391,722 | 0.01% |
| Millennium Management LLC | 1,508,478 | 4.80% | $8.57M | +639,221 | 0.00% |
| Vanguard Capital Management LLC | 1,097,755 | 3.49% | $6.24M | +56,567 | 0.00% |
| 72 Investment Holdings, LLC | 1,017,751 | 3.24% | $5.78M | – | 11.57% |
| Blue Owl Capital Holdings LP | 756,722 | 2.41% | $4.30M | +250,000 | 0.65% |
| C WorldWide Group Holding A/S | 700,000 | 2.23% | $3.98M | – | 0.10% |
| Geode Capital Management, LLC | 564,662 | 1.80% | $3.21M | +40,088 | 0.00% |
| Trexquant Investment LP | 497,526 | 1.58% | $2.83M | +283,118 | 0.02% |
| Marshall Wace, Llp | 493,099 | 1.57% | $2.80M | +332,835 | 0.00% |
| Qube Research & Technologies Ltd | 482,195 | 1.53% | $2.74M | New | 0.00% |
| Morgan Stanley | 472,995 | 1.51% | $2.69M | −175,853 | 0.00% |
| Primecap Management Co/Ca/ | 472,200 | 1.50% | $2.68M | – | 0.00% |
| Tang Capital Management LLC | 451,114 | 1.44% | $2.56M | – | 0.12% |
| Alyeska Investment Group, L.P. | 438,882 | 1.40% | $2.49M | −24,613 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 144 | 35M | 100.0% | 28 / 59 | 34 / 27 | 5M | 3M |
| Q1 2026 | 145 | 33M | 100.0% | 35 / 57 | 28 / 48 | 7M | 8M |
| Q4 2025 | 161 | 35M | 100.0% | 50 / 53 | 33 / 55 | 13M | 7M |
| Q3 2025 | 166 | 29M | 92.8% | 57 / 64 | 24 / 4 | 8M | 3M |
| Q2 2025 | 113 | 25M | 78.8% | 24 / 54 | 15 / 16 | 5M | 1M |
| Q1 2025 | 105 | 21M | 67.1% | 24 / 30 | 27 / 12 | 3M | 2M |
| Q4 2024 | 94 | 20M | 63.2% | 24 / 32 | 21 / 8 | 2M | 1M |
| Q3 2024 | 78 | 19M | 59.6% | 23 / 20 | 16 / 9 | 2M | 2M |
| Q2 2024 | 65 | 19M | 60.2% | 19 / 26 | 6 / 9 | 3M | 0M |
| Q1 2024 | 55 | 16M | 51.8% | 55 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
151 funds held LENZ in Q1 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LENZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,228,633 | 3.91% | $9.56M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 819,606 | 2.61% | $4.66M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 538,648 | 1.71% | $3.06M | 0.00% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 406,400 | 1.29% | $2.15M | 0.03% | Jul 31, 2026 |
| Fidelity Series Growth Company Fund | 314,100 | 1.00% | $2.44M | 0.01% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 313,056 | 1.00% | $2.44M | 0.01% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 253,113 | 0.81% | $1.44M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 225,784 | 0.72% | $1.20M | 0.00% | Jul 31, 2026 |
| iShares Biotechnology ETF | 193,013 | 0.61% | $1.10M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 172,550 | 0.55% | $980.08K | 0.01% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 104,012 | 0.33% | $809.21K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 101,792 | 0.32% | $791.94K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 68,937 | 0.22% | $391.56K | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 59,341 | 0.19% | $461.67K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 56,217 | 0.18% | $297.95K | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Evert B. Schimmelpennink | President, CEO and Secretary, Director | 77,289 | 0.25% | Mar 30, 2026 |
| Daniel R. Chevallard | Chief Financial Officer | 12,886 | 0.04% | Nov 3, 2026 |
| Marc Odrich | Chief Medical Officer | 99,599 | 0.32% | Jan 6, 2026 |
| Shawn Olsson | Chief Commercial Officer | 4,733 | 0.02% | Jan 6, 2026 |
| Shelley B. Thunen | Director | – | – | Jun 15, 2026 |
| Kimberlee C. Drapkin | Director | – | – | Jun 15, 2026 |
| James W. McCollum | Director | 631,099 | 2.01% | Jun 15, 2026 |
| Zachary Scheiner | Director | – | – | Jun 15, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 164,729 | 0.52% | Jun 15, 2026 |
| Frederic Guerard | Director | – | – | Jun 15, 2026 |
| Jeffrey P. George | Director | 5,592 | 0.02% | Jun 15, 2026 |
| Peter Kolchinsky | 10% owner | – | – | Nov 2, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Nov 2, 2026 |
| Ra Capital Management, L.P. | 10% owner | 57,559 | 0.18% | Nov 2, 2026 |
| Rajeev M. Shah | 10% owner | – | – | Nov 2, 2026 |
| Versant Ventures VII GP-GP, LLC | 10% owner | 2,623,811 | 8.35% | Oct 2, 2025 |
| Versant Venture Capital VI, L.P. | 10% owner | 2,916,537 | 9.28% | Oct 2, 2025 |
| Versant Ventures VI GP-GP, LLC | 10% owner | 2,364,671 | 7.53% | Oct 2, 2025 |
| Versant Ventures VI GP, L.P. | 10% owner | 3,015,187 | 9.60% | Oct 2, 2025 |
| Versant Vantage II, L.P. | 10% owner | – | – | Oct 2, 2025 |
| Versant Vantage II GP, L.P. | 10% owner | 4,542,150 | 14.46% | Oct 2, 2025 |
| Versant Vantage II GP-GP, LLC | 10% owner | 2,636,478 | 8.39% | Oct 2, 2025 |
| Versant Venture Capital VII, L.P. | 10% owner | 1,598,789 | 5.09% | Oct 2, 2025 |
| Versant Ventures VII GP, L.P. | 10% owner | 3,101,944 | 9.87% | Oct 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. 10% owner | Oct 29, 2026 | Sale | −107,170 | $3.36 | $360.09K | 57,559 |
| Ra Capital Management, L.P. 10% owner | Oct 29, 2026 | Sale | −451,998 | $3.36 | $1.52M | 242,757 |
| Ra Capital Management, L.P. 10% owner | Oct 29, 2026 | Sale | −2,159,516 | $3.36 | $7.26M | 1,159,823 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Mar 27, 2026 | Buy | +28,089 | $8.95 | $251.40K | 77,289 |
| Daniel R. Chevallard Chief Financial Officer | Mar 27, 2026 | Buy | +7,500 | $8.57 | $64.28K | 12,886 |
| Jeffrey P. George Director | Mar 27, 2026 | Buy | +5,592 | $8.92 | $49.88K | 5,592 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −5,788 | $26.37 | $152.63K | 4,733 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −4,212 | $25.74 | $108.42K | 10,521 |
| Shawn Olsson Chief Commercial Officer | Nov 17, 2025 | Option exercise | +10,000 | $2.08 | $20.80K | 14,733 |
| James W. McCollum Director | Nov 7, 2025 | Buy | +10,500 | $22.79 | $239.30K | 10,500 |
| Daniel R. Chevallard Chief Financial Officer | Nov 7, 2025 | Buy | +20 | $22.71 | $454 | 3,208 |
| Daniel R. Chevallard Chief Financial Officer | Nov 7, 2025 | Buy | +2,178 | $22.76 | $49.57K | 5,386 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −123 | $47.01 | $5.78K | 764,127 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −177 | $47.01 | $8.32K | 1,050,599 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −57,502 | $46.41 | $2.67M | 764,250 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −83,066 | $46.41 | $3.86M | 1,050,776 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −49,701 | $45.35 | $2.25M | 1,133,842 |
| Versant Vantage II GP-GP, LLC 10% owner | Sep 30, 2025 | Sale | −34,405 | $45.35 | $1.56M | 821,752 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −40,907 | $43.00 | $1.76M | 1,183,811 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −268 | $43.30 | $11.60K | 1,183,543 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −20,148 | $43.00 | $866.36K | 856,289 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −132 | $43.30 | $5.72K | 856,157 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −24,370 | $41.59 | $1.01M | 876,437 |
| Versant Venture Capital VI, L.P. 10% owner | Sep 18, 2025 | Sale | −49,479 | $41.59 | $2.06M | 1,224,718 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −21,661 | $38.97 | $844.13K | 902,514 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −3,465 | $39.50 | $136.87K | 1,274,197 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −1,707 | $39.50 | $67.43K | 900,807 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 26, 2025 | Sale | −43,978 | $38.97 | $1.71M | 1,277,662 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −2,149 | $39.92 | $85.79K | 1,321,640 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −24,760 | $39.53 | $978.76K | 925,233 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −50,270 | $39.53 | $1.99M | 1,323,789 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 25, 2025 | Sale | −1,058 | $39.92 | $42.24K | 924,175 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −10,076 | $40.03 | $403.34K | 952,802 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −2,809 | $40.59 | $114.02K | 949,993 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −5,668 | $40.59 | $230.06K | 1,374,059 |
| Versant Ventures VII GP, L.P. 10% owner | Aug 22, 2025 | Sale | −20,493 | $40.03 | $820.33K | 1,379,727 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 18, 2025 | Sale | −30,628 | $38.56 | $1.18M | 1,400,220 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 18, 2025 | Sale | −15,085 | $38.56 | $581.68K | 962,878 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 15, 2025 | Sale | −145,051 | $39.50 | $5.73M | 1,430,848 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 15, 2025 | Sale | −69,949 | $39.50 | $2.76M | 977,963 |
| Versant Ventures VII GP-GP, LLC 10% owner | Jul 10, 2025 | Sale | −191,376 | $34.00 | $6.51M | 1,575,899 |
| Versant Vantage II GP-GP, LLC 10% owner | Jun 27, 2025 | Sale | −200,000 | $30.47 | $6.09M | 1,767,275 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 20, 2025 | Sale | −133,924 | $30.25 | $4.05M | 1,967,275 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 20, 2025 | Sale | −100,877 | $30.35 | $3.06M | 1,047,912 |
| Versant Ventures VI GP, L.P. 10% owner | Jun 18, 2025 | Sale | −100,000 | $29.95 | $3.00M | 1,148,789 |
| Versant Vantage II GP-GP, LLC 10% owner | Jun 10, 2025 | Sale | −350,000 | $29.00 | $10.15M | 1,248,789 |
| Shawn Olsson Chief Commercial Officer | Apr 9, 2025 | Option exercise | +1,400 | $2.08 | $2.91K | 4,733 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Mar 7, 2025 | Option exercise | +4,200 | $1.04 | $4.37K | 49,200 |
| Shawn Olsson Chief Commercial Officer | Dec 16, 2024 | Option exercise | +3,333 | $2.08 | $6.93K | 3,333 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director | Jul 22, 2024 | Option exercise | +45,000 | $1.04 | $46.80K | 45,000 |
| Daniel R. Chevallard Chief Financial Officer | May 14, 2024 | Buy | +3,188 | $15.68 | $49.99K | 3,188 |
| James W. McCollum Director | May 13, 2024 | Buy | +31,332 | $15.99 | $501.00K | 525,565 |
| James W. McCollum Director | Mar 21, 2024 | Award | +16,633 | $15.03 | $249.99K | 494,233 |
| James W. McCollum Director | Mar 21, 2024 | Award | +477,600 | – | – | 477,600 |
| James W. McCollum Director | Mar 21, 2024 | Award | +95,034 | – | – | 95,034 |
| Marc Odrich Chief Medical Officer | Mar 21, 2024 | Award | +99,599 | – | – | 99,599 |
| Versant Vantage II GP, L.P. 10% owner | Mar 21, 2024 | Other | +598,203 | – | – | 842,162 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +164,729 | – | – | 164,729 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +694,755 | – | – | 694,755 |
| RA Capital Nexus Fund II, L.P. Director, 10% owner | Mar 21, 2024 | Award | +2,386,301 | – | – | 2,386,301 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LENZ Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 76,786 shares on Sep 23, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shawn Olsson Officer | Nov 17, 2025 | 40,000 | $1.02M | Nov 17, 2025 | Exercise of Stock Options |
See a number that looks wrong?